Epidemiology of Mpox Cases, and Tecovirimat and JYNNEOS Utilization, Alameda County, California, June-October 2022
- PMID: 39041768
- DOI: 10.1097/PHH.0000000000002010
Epidemiology of Mpox Cases, and Tecovirimat and JYNNEOS Utilization, Alameda County, California, June-October 2022
Abstract
Context: The 2022 United States mpox outbreak disproportionately affected racial and ethnic minority gay, bisexual, and other men who have sex with men.
Program: We utilized surveillance data and vaccination registries to determine whether populations most impacted by mpox in Alameda County received JYNNEOS vaccines and tecovirimat (TPOXX) during June 1-October 31, 2022.
Implementation: Alameda County Public Health Department responded to the mpox epidemic through partnerships with local health care providers who serve communities disproportionately affected by mpox.
Evaluation: During June 1-October 31, 2022, a total of 242 mpox cases were identified in Alameda County. Mpox incidence rates per 100 000 were highest among Black/African American (35.7; 95% confidence interval [CI], 26.8-46.5) and Hispanic/Latinx (25.1; CI, 20.1-30.9) residents, compared to Asian (3.8; CI, 2.3-5.9) and White (10.5; CI, 7.7-13.9) residents. Most confirmed cases were identified as gay, lesbian, or same-gender-loving (134, 67.3%) and bisexual (31, 15.6%); 226 (93.8%) cases were male. Sixty-nine (28.5%) mpox patients received TPOXX. There were no statistically significant differences in demographic and clinical characteristics of mpox cases when compared by TPOXX receipt status. JYNNEOS vaccine was received by 8277 Alameda County residents. The largest proportion of vaccinees were White residents (40.2%). Administration rates per 100 000 men who have sex with men were lowest among Asian and Hispanic/Latinx individuals, at 8779 (CI, 8283-9296) and 14 953 (CI, 14 156-15 784), respectively. Black/African American and Hispanic/Latinx males had the lowest vaccination-to-case ratios at 16.7 and 14.8, respectively.
Discussion: Mpox disproportionately affected Black/African American and Hispanic/Latinx men who have sex with men in Alameda County. Strong partnerships with local health care providers ensured that persons with mpox received TPOXX treatment when indicated. However, higher JYNNEOS vaccine uptake in Black and Latinx communities needs improvement through ongoing and meaningful engagement with Black/African American and Hispanic/Latinx gay, bisexual, and transgender communities.
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Conflict of interest statement
The authors declare that they have no conflicts of interest.
Similar articles
-
Reducing Vaccination Disparities During a National Emergency Response: The US Mpox Vaccine Equity Pilot Program.J Public Health Manag Pract. 2024 Jan-Feb 01;30(1):122-129. doi: 10.1097/PHH.0000000000001818. Epub 2023 Aug 21. J Public Health Manag Pract. 2024. PMID: 37678261 Free PMC article.
-
Vaccine Effectiveness of JYNNEOS against Mpox Disease in the United States.N Engl J Med. 2023 Jun 29;388(26):2434-2443. doi: 10.1056/NEJMoa2215201. Epub 2023 May 18. N Engl J Med. 2023. PMID: 37199451 Free PMC article.
-
Health insurance status and severe mpox disease outcomes among sexual minority men in NYC: a retrospective cohort study.BMC Med. 2025 Jul 9;23(1):418. doi: 10.1186/s12916-025-04252-2. BMC Med. 2025. PMID: 40629412 Free PMC article.
-
Behavioral interventions to reduce risk for sexual transmission of HIV among men who have sex with men.Cochrane Database Syst Rev. 2008 Jul 16;(3):CD001230. doi: 10.1002/14651858.CD001230.pub2. Cochrane Database Syst Rev. 2008. PMID: 18646068
-
Mpox Clinical Presentation, Diagnostic Approaches, and Treatment Strategies: A Review.JAMA. 2024 Nov 19;332(19):1652-1662. doi: 10.1001/jama.2024.21091. JAMA. 2024. PMID: 39401235 Review.
Cited by
-
Harnessing Nanohybridized Niclosamide for Precision Mpox Therapeutics.Adv Healthc Mater. 2025 May;14(14):e2404818. doi: 10.1002/adhm.202404818. Epub 2025 Feb 23. Adv Healthc Mater. 2025. PMID: 39988865 Free PMC article. Review.
-
The resurgence of monkeypox: Epidemiology, clinical features, and public health implications in the post-smallpox eradication era.New Microbes New Infect. 2024 Sep 24;62:101487. doi: 10.1016/j.nmni.2024.101487. eCollection 2024 Dec. New Microbes New Infect. 2024. PMID: 39429728 Free PMC article. Review.
References
-
- Ranjan R, Biswal JK. Monkeypox: re-emerging zoonotic threat. Zoonotic Dis. 2022;2(4):234-246.
-
- McQuiston JH, Braden CR, Bowen MD, et al. The CDC domestic mpox response—United States, 2022–2023. MMWR Morb Mortal Wkly Rep. 2023;72(20):547-552.
-
- Monkeypox update: FDA authorizes emergency use of JYNNEOS vaccine to increase vaccine supply. FDA. https://www.fda.gov/news-events/press-announcements/monkeypox-update-fda... . August 9, 2022. Accessed September 19, 2023.
-
- Dalton AF, Diallo AO, Chard AN, et al. Estimated effectiveness of JYNNEOS vaccine in preventing Mpox: a multijurisdictional case-control study — United States, August 19, 2022–March 31, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(20):553-558.
-
- Deputy NP, Deckert J, Chard AN, et al. Vaccine effectiveness of JYNNEOS against mpox disease in the United States. N Engl J Med. 2023;388(26):2434-2443.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources